MILPHARM ApS
CVRCVR number35814159Opløst
Company financials
Key figures
Updated 14 Feb 2022
- Return on assets
- -0.1%
- Return on equity
- 28.6%
- Current ratio
- 188%
- Equity ratio
- 46.8%
Profit and loss
| Reporting period | |
|---|---|
Gross profit | -1,867 |
Operating profit | -1,867 |
Finance income | 248,071 |
Finance expenses | 22,429 |
Tax expense | 48,094 |
Profit/loss for the year | 175,681 |
Employees
| Reporting period | |
|---|---|
Avg. employees | 0 |
Balance sheet
| Reporting period | |
|---|---|
Cash and cash equivalents | 7,588 |
Current assets | 1,313,472 |
Total assets | 1,313,472 |
Equity | 614,869 |
Liabilities | 698,603 |
Current liabilities | 698,603 |
Working capital
| Reporting period | |
|---|---|
Trade payables | 6,000 |
Capital and dividend
| Reporting period | |
|---|---|
Contributed capital | 50,000 |
Retained earnings | 564,869 |
Investments and assets
| Reporting period | |
|---|---|
Short-term investments | 1,305,884 |
Other securities | 1,305,884 |
Annual report highlights
Official annual report · 2021
Business and development
Primary activities
Selskabets formål er at drive investeringsvirksomhed.
Væsentlige ændringer i aktiviteter og økonomiske forhold
Selskabet har i året et overskud, hvilket ledelsen anser for tilfredsstillende.
Risks and material matters
Significant events after the reporting period
Der er ikke efter regnskabsårets slutning indtruffet begivenheder, som i væsentlig grad påvirker bedømmelsen af det opnåede resultat eller selskabets økonomiske stilling pr. statusdagen.
Create a free account to see up to 9 years of financial history
Create free account